Background Although effective in reducing blood pressure, therapy with a first-generation β-
blocker is currently controversial in metabolic syndrome due to its negative impact on …

Objective Atenolol, a first-generation β-blocker, effectively reduces blood pressure, although
its use in metabolic syndrome remains controversial. Accordingly, this study evaluated the …

Objective To obtain further insight into the mechanism underlying the vasodilator effect of
nebivolol. Since oxidative inactivation of nitric oxide (NO) is regarded as an important cause …

The aim was to evaluate the effects and mechanisms of nebivolol on renal damage in
Zucker diabetic fatty (ZDF) rats, in comparison with those of atenolol and captopril. Animals …

This study aims to decipher the potential effects of nebivolol in prevention and/or regression
of renal artery dysfunction in diabetes associated with hypertension. Renal arteries were …

Blood pressure management in hypertensive patients with metabolic abnormalities is
challenging, since many of the antihypertensive drugs adversely affect metabolism. Besides …

Background: In patients with diabetes mellitus type 2 and arterial hypertension, the control of
systolic and diastolic blood pressure is essential to reduce the risk of adverse events. The …

Objectives We observed previously that nebivolol treatment for 2 months reduced
cardiovascular lesions in spontaneously hypertensive rats (SHR). Therefore, we …

Oxidative stress and endothelial dysfunction have been associated with essential
hypertension (EH) mechanisms. The purpose of this study was to evaluate the effect of …

Abstract β-Adrenergic blockers are no longer recommended as first-line therapy due to the
reduced cardioprotection of traditional β-blockers compared with other antihypertensive …